Anavex Life Sciences Corp (AVXL)

[falconer66a]

The Blarcamesine Anti-aging Factor

Just read a new article in the October The Scientist, “a magazine for life science professionals,” entitled "Accurate Protein Production Promotes Longevity." Very important for Anavex science.

The article summarized this paper in Cell Metabolism:
https://www.sciencedirect.com/science/article/pii/S1550413121004174?via%3Dihub

The Scientist article stated, “As an organism ages, the efficiency and accuracy of its cellular processes deteriorate. For example, protein production, folding, and degradation all decline in quality, such that loss of protein homeostasis (proteostasis), is ‘a major hallmark of aging’ and age-related diseases, says molecular biologist Patricija van Oosten-Hawle of the University of Leeds....”

For Anavex, the important matter is this. Both of the Anavex sigma-1 receptor agonists (activators), blarcamesine (Anavex 2-73) and Anavex 3-71, restore or promote proper protein synthesis and, especially, protein folding. Misfolded proteins, usually in the proteins of reaction-controlling enzymes, are the source of a host of aging and neurodegenerative diseases; causing dementia and other neurological dysfunctions.

The potential take-away? The Anavex molecules very likely will slow, stop, or reverse various aging processes occurring in the central nervous system; and, perhaps in other body systems.

Will blarcamesine be the first, effective Ponce de León Effect drug, usefully and safely preserving or restoring youthful functions and processes in aging humans?

As I've contended before, Anavex has most likely already checked this with Caenorhabditis elegans, a common, well-characterized lab roundworm used in aging studies. The time is not yet appropriate for Dr. Missling to lay out what Anavex knows about blarcamesine working its anti-aging processes in lab roundworms. For the nonce, I'll take the criticisms. Dr. Missling can announce the findings of his studies after it is recognized that blarcamesine really does work in two or three big CNS diseases in humans, next year.